News

June 7, 2016 In Press Releases

InCarda Therapeutics Elects Dr. Norbert Bischofberger to Board of Directors

San Francisco, California, June 7, 2016 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development of therapies for cardiovascular conditions via the inhalation route, today announced the election of Norbert Bischofberger, Ph.D., to the company’s board of directors. Dr. Bischofberger has...

December 1, 2015 In Press Releases

InCarda Therapeutics Establishes Subsidiary Business in Australia

San Francisco, California, December 1, 2015 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development and commercialization of therapies for cardiovascular conditions via the inhalation route, today announced that it has established a subsidiary business in Australia. InCarda is planning to...

October 6, 2015 In Press Releases

InCarda Therapeutics Issued Broad Patents in U.S., Australia and Canada

Palo Alto, California, October 6, 2015 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development and commercialization of therapies for acute cardiovascular conditions via the inhalation route, today announced the issuance of patents in the United States, Australia and Canada, which...

April 28, 2015 In Press Releases

InCarda Therapeutics Completes Over $5 Million Private Financing

San Francisco, California, April 28, 2015 – InCarda Therapeutics, Inc. (InCarda), a privately-­‐held biotechnology company focused on the development and commercialization of therapies for acute cardiovascular conditions via the inhalation route, today announced the completion of a Series A financing. In this financing, InCarda raised...